NICE promotes the use of SIRT using SIR-Spheres in England and Wales as a fully funded and reimbursed alternative for adult patients with HCC
FREMONT, CA: Sirtex Medical US Holdings (Sirtex), a leading maker of targeted cancer therapies, received positive guidance from the National Center for Health and Care Excellence (NICE). They received it for the use of Selective Internal Radiation Therapy (SIRT) with SIR-Spheres Y-90 microspheres for the treatment of adults with unresectable advanced Hepatocellular Carcinoma (HCC).
“HCC is the most common form of liver cancer in England, with more than 6,000 new liver cancer cases in the United Kingdom each year,” said Kevin R. Smith, Chief Executive Officer, Sirtex. “We celebrate the availability of SIR-Spheres in England and Wales as a significant step forward in care for patients with HCC.”
“It is excellent news that NICE has recommended SIRT for the treatment of HCC,” commented Dr. Paul Ross, Consultant Medical Oncologist at Guy’s & St. Thomas’ NHS Foundation Trust and Clinical Lead for HCC at King’s College Hospital. “The expanded options will advance the quality of life for patients and provide meaningful alternatives to existing treatments.”
NICE promotes the use of SIRT using SIR-Spheres in England and Wales as a fully funded and reimbursed alternative for adult patients with HCC, on the grounds that it is used for people with Child-Pugh grade A liver disability when traditional transarterial therapies are inadequate and that the organization offers SIR-Spheres.
“The decision by NICE to approve SIRT is an enormous relief for patients with HCC, who often have limited options and now have a guarantee of access to treatment when needed,” said Dr. Damian Mullan, Consultant Interventional Radiologist, Christie Hospital Manchester. “SIRT has been shown to be a cost-effective use of resources for the NHS, which is especially important during the ongoing COVID-19 pandemic.”
NICE produces evidence-based guidance and advice for health, public health, and social care professionals as part of the National Health Service (NHS) for England and Wales. Based on clinical and health economic data submitted by Sirtex during the multiple technology assessment processes, NICE proposed SIR-Spheres as a treatment choice for HCC.
“The British Liver Trust is delighted that NICE has now approved the use of SIRT as an option for treating unresectable advanced HCC in adults,” said Pamela Healy, OBE, Chief Executive, British Liver Trust. “HCC is the most common form of liver cancer. It is particularly aggressive and a diagnosis is devastating for patients, carers and their families. Treatment options for patients with advanced liver cancer have been very limited and this decision will make this innovative treatment more easily available and improve options for patients. Evidence shows that outcomes for people with advanced liver cancer are particularly poor so this is a very important step.”